Golden
Roche

Roche

No article has been written about this topic yet.
Paste a URL about this topic to auto-extract knowledge.
Visit our Writing Guide for help on how to write about a topic,
and check out an example of a well filled out topic page.

No article has been written about this topic yet.
Be the first one to add some text.

Loading AI-assisted edit mode...

Timeline

People

Name
Role
LinkedIn







Further reading

Title
Author
Link
Type
Date









Documentaries, videos and podcasts

Title
Date
Link





Companies

Company
CEO
Location
Products/Services









News

Title
Author
Date
Publisher
Description
Reuters Editorial
December 23, 2019
U.S.
Roche entered into a $1.15 billion licensing agreement with Sarepta Therapeutics to obtain the right to launch and commercialize Sarepta's investigational gene therapy for Duchenne muscular dystrophy (DMD) outside the United States.
Reuters
December 17, 2019
@bsindia
Read more about Roche to complete $4.3 bn acquisition of Spark as regulators give all clear on Business Standard. The Federal Trade Commission (FTC) and Britain's Competition and Markets Authority (CMA) approved the deal on Monday without demanding asset sales
Diane Bartz
December 17, 2019
IN
Swiss drugmaker Roche plans to complete its $4.3 billion takeover of gene therapy specialist Spark Therapeutics on Tuesday after U.S. and British authorities ruled the deal would not hurt competition in hemophilia A treatment.
Reuters Editorial
December 16, 2019
U.S.
Swiss drugmaker Roche has won U.S. antitrust approval for its $4.3 billion deal to buy gene therapy specialist Spark Therapeutics clearing the way for Roche's push into treating rare diseases including hemophilia A.
Maija Palmer
November 26, 2019
Sifted
A roundup of the what Europe's biggest companies are doing with startups and new technologies, from Amadeus to BASF and Telefónica.
Reuters Editorial
November 25, 2019
IN
Roche expects its risdiplam medicine for spinal muscular atrophy (SMA) to get U.S. approval by May, the Swiss drugmaker said on Monday, as it takes on Novartis and Biogen in the lucrative rare disease area.
November 11, 2019
WebWire
Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced positive data from the pivotal Part 2 of SUNFISH, a study evaluating risdiplam in people aged 2-25 years with Type 2 or 3 spinal muscular atrophy (SMA). The study met its primary endpoint of change from baseline in the Motor Function Measure 32 (MFM-32) scale after one year of treatment with risdiplam, compared to placebo. No treatment related safety findings leading to study withdrawal have been seen in any risdiplam trial to date. Safety...
Reuters Editorial
October 24, 2019
U.S.
The Federal Trade Commission staff reviewing Roche's plan to buy U.S.-based gene therapy specialist Spark Therapeutics for $4.3 billion recommended that the deal be approved without requiring any asset sales, the Capitol Forum reported on Thursday.
October 15, 2019
WebWire
, , , , • 40% of patients with pemphigus vulgaris (PV) achieved sustained complete remission, without the use of steroids for 16 weeks or more, when treated with MabThera/Rituxan compared to 9.5% of patients on mycophenolate mofetil , , • Study reinforces efficacy and safety of MabThera/Rituxan for treatment of PV, a rare autoimmune condition characterised by blistering of the skin and mucous membranes , , • Full data of the 52-week treatment period presented at 28th Congress of the European Ac...
John Miller
October 10, 2019
IN
A member of Swiss drugmaker Roche's controlling family said on Wednesday that short-term profit maximization has "destroyed the planet" and the world needs a new breed of capitalism putting long-term interests first.
September 30, 2019
WebWire
Roche (SIX: RO, ROG; OTCQX: RHHBY) and Spark Therapeutics, Inc. (NASDAQ: ONCE) ("Spark") today announced that Roche has extended the offering period of its previously announced tender offer to purchase all of the outstanding shares of common stock (the "Shares") of Spark for USD 114.50 per Share, net to the seller thereof in cash, without interest and subject to any withholding taxes required by applicable law and upon the terms and subject to the conditions set forth in the Offer to Purch...
Reuters Editorial
June 11, 2019
U.S.
Swiss drugmaker Roche on Tuesday named a new head of its $13-billion-per-year diagnostics business and also said board member Peter Voser is stepping down to focus on his expanded duties as interim head of Swiss engineering group ABB.
John Miller
June 10, 2019
U.S.
Swiss drugmaker Roche's $4.3 billion takeover of U.S. gene therapy specialist Spark Therapeutics has been pushed back again, possibly beyond the first half, as regulators continue to scrutinize the deal for its effect on competition.
Nimble Therapeutics
April 30, 2019
www.prnewswire.com:443
MADISON, Wis., April 30, 2019 /PRNewswire/ -- Nimble Therapeutics has begun operating as a standalone business after spinning out from F. Hoffmann La Roche...
Reuters Editorial
March 29, 2019
U.S.
AstraZeneca Plc and Japan's Daiichi Sankyo Co Ltd have signed a potential multibillion-dollar collaboration to develop and sell Daiichi's cancer drug trastuzumab deruxtecan.
Reuters Editorial
March 26, 2019
U.S.
Swiss drugmaker Roche will close its manufacturing plant in the Brazilian city of Rio de Janeiro, shuttering operations over the next five years before selling the plot, the company said in a statement on Tuesday.
March 18, 2019
WebWire
, , , , • MabThera is the first biologic treatment approved for moderate to severe cases of the rare autoimmune disease pemphigus vulgaris (PV), and the first major advancement in the treatment of the disease in more than 60 years , , • PV is a rare and potentially life-threatening blistering condition which can cause severe pain and disfigurement , , • MabThera is now approved in Europe to treat four autoimmune diseases , , , , , , Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the Europe...
February 22, 2019
WebWire
Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the US Food and Drug Administration (FDA) has accepted the company's New Drug Applications (NDAs) and granted Priority Review for entrectinib for the treatment of adult and paediatric patients with neurotrophic tropomyosin receptor kinase (NTRK) fusion-positive, locally advanced or metastatic solid tumours who have either progressed following prior therapies or as an initial therapy when there are no acceptable standard therapies, and...
Best Places to Work Limited
Invalid Date
www.prnewswire.com:443
ALGIERS, Algeria, Feb. 18, 2019 /PRNewswire/ -- Roche, Novartis, Ipsen, Amana, Tango and Redmed group were recognized yesterday as the Best Places to Work in...
February 5, 2019
WebWire
Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced completing the submission of a supplemental Biologics License Application to the US Food and Drug Administration (FDA) for Kadcyla® (trastuzumab emtansine) for adjuvant (after surgery) treatment of people with HER2-positive early breast cancer (eBC) with residual disease after neoadjuvant (before surgery) treatment. The FDA is reviewing the application under the Real-Time Oncology Review and Assessment Aid pilot programmes, which aim to e...
SHOW MORE